Narrative review / 2000
Collagen hydrolysate shows potential therapeutic utility in osteoarthritis and osteoporosis, with a high level of safety.
This review examined literature on collagen hydrolysate metabolism and clinical trials in osteoarthritis and osteoporosis. Clinical studies suggest that taking 10 g of pharmaceutical-grade collagen hydrolysate (PCH) daily reduces pain in knee or hip osteoarthritis, though a multicenter randomized trial found no overall statistically significant difference in mean pain scores across all sites (showing benefit primarily at German sites and among patients with more severe baseline symptoms). In osteoporosis studies, combining calcitonin with a collagen hydrolysate-rich diet produced a greater reduction in urinary pyridinoline cross-links than calcitonin alone. Reported adverse effects were minimal, mainly involving fullness or unpleasant taste.
- Study type
- Literature review
- Who was studied
- Patients with osteoarthritis or osteoporosis in clinical studies
- What was measured
- Pain scores, cartilage metabolism, and markers of bone collagen breakdown
THE PAPER
Role of collagen hydrolysate in bone and joint disease.
Moskowitz RW. Semin Arthritis Rheum, 2000.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.